1 / 4

Volasertib Combined with Low Dose Cytarabine in AML: Genetic Data Focus

Assessing the efficacy of volasertib + LDAC vs. LDAC alone in untreated AML patients ineligible for intensive treatment. Study outcomes include treatment response and event-free survival. Updated data from EHA 2013 clinical trial snapshot.

ryo
Download Presentation

Volasertib Combined with Low Dose Cytarabine in AML: Genetic Data Focus

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Étude de phase II : volasertib (BI 6727)+ cytarabine faible dose (LDAC) versus LDACdans la LAM : focus sur les données de génétique Bras contrôleLDAC 2 x 20 mg/j s.c., J1-J10 /28j n = 43 LAM non antérieurement traitée Patients adultes non éligiblesà un traitement intensif R 1:1 n = 43 Bras expérimental LDAC 2 x 20 mg/j s.c., J1-J10 + Volasertib (350 mg) J1 + J15 /28j EHA 2013 - D’après Döhner H et al., abstract S587, actualisé

  2. Caractéristiques initiales des patients EHA 2013 - D’après Döhner H et al., abstract S587, actualisé

  3. Réponse au traitement* OR : 2,91 ; p = 0,0523. *Clinical trial ongoing, databasesnapshot 30 oct. 2012, data on file. EHA 2013 - D’après Döhner H et al., abstract S587, actualisé

  4. Survie sans événement* Survie globale médiane *Clinical trial ongoing, databasesnapshot 30 oct. 2012, data on file. EHA 2013 - D’après Döhner H et al., abstract S587, actualisé

More Related